1. Home
  2. RYM vs NSPR Comparison

RYM vs NSPR Comparison

Compare RYM & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RYM

RYTHM Inc.

N/A

Current Price

$24.72

Market Cap

60.2M

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.02

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYM
NSPR
Founded
2016
2005
Country
United States
United States
Employees
141
N/A
Industry
Farming/Seeds/Milling
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.2M
72.1M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
RYM
NSPR
Price
$24.72
$1.02
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
6.5K
242.5K
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
N/A
$57.98
Revenue Next Year
N/A
$95.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.00
$0.86
52 Week High
$53.65
$2.93

Technical Indicators

Market Signals
Indicator
RYM
NSPR
Relative Strength Index (RSI) 43.87 41.66
Support Level $24.33 N/A
Resistance Level $30.35 $1.29
Average True Range (ATR) 1.51 0.07
MACD -0.41 0.01
Stochastic Oscillator 9.93 40.18

Price Performance

Historical Comparison
RYM
NSPR

About RYM RYTHM Inc.

Rythm Inc is a USA Based company. The company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: